TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05957081: A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced or Metastatic So

Sponsor: PharmAbcine · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 67 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,005,768

Rescue Site Savings

+$4,618,152

Unlock Full NCT05957081 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05957081 Rescue Dossier →